In 2020, Pfizer spun off its entire portfolio of older drugs, shed a third of its revenue, and declared itself a pure-play innovator. Months later, it delivered a COVID-19 vaccine in under a year. The American pharmaceutical giant posted $63.6 billion in revenue in 2024 with 81,000 employees and holds 1,037 patent filings in India alone.
For most of the 2010s, Pfizer was the largest pharmaceutical company on earth by a metric that no longer mattered. Its revenue in 2014 was $49.6 billion, built on a portfolio that stretched from patented biologics to off-patent generics, from hospital injectables to over-the-counter consumer products. The breadth was its identity. It was also its problem. Analysts valued diversified pharma conglomerates at a discount to focused innovators, and Pfizer’s leadership knew it.
The dismantling was methodical. In 2019, Pfizer folded its consumer healthcare business into a joint venture with GSK, creating what would eventually become Haleon, a standalone consumer health company. That removed brands like Advil and Centrum from Pfizer’s books. Then came the larger surgery. In November 2020, Pfizer completed the spinoff of Upjohn, its division of established and off-patent medicines, merging it with generic drugmaker Mylan to form Viatris. Lipitor, Viagra, Lyrica, Norvasc,the drugs that had defined Pfizer for a generation,left with Upjohn.
The financial consequence was immediate and brutal. Revenue in 2020 fell to $41.9 billion, down from $51.8 billion the prior year. Pfizer had voluntarily amputated roughly a fifth of its top line. What remained was a company organized around two priorities: developing novel medicines and manufacturing them at scale. The bet was that a focused Pfizer would grow faster, attract a higher valuation multiple, and produce better science than a diversified one. By 2024, revenue had climbed to $63.6 billion. The bet paid.
The partnership with BioNTech was not inevitable. In early 2020, Pfizer was one of dozens of pharmaceutical companies evaluating COVID-19 vaccine candidates, and BioNTech was a mid-sized German biotech that had never brought a product to market. What Pfizer had that BioNTech lacked was manufacturing infrastructure, regulatory experience across dozens of national agencies, and the financial capacity to run parallel clinical trials without waiting for results from each phase before starting the next. What BioNTech had was the mRNA platform.
The timeline that followed became the defining pharmaceutical story of the decade. Pfizer and BioNTech announced their collaboration in March 2020. The Phase 3 trial enrolled 43,661 participants across 150 sites in six countries. On November 18, 2020, they reported 95 per cent efficacy. On December 11, the FDA issued Emergency Use Authorization. Between announcement and authorization: 274 days. The standard vaccine development timeline, from preclinical work to approval, typically runs eight to fifteen years.
The manufacturing challenge was as formidable as the science. mRNA vaccines require storage at minus 70 degrees Celsius, a cold-chain specification that did not exist at commercial scale anywhere in the world. Pfizer built it. The company repurposed and expanded facilities in Kalamazoo, Michigan, and Puurs, Belgium, ultimately producing billions of doses. Revenue surged: from $41.9 billion in 2020 to $51.8 billion in 2021 and $57.0 billion in 2022. The COVID-19 vaccine did not just validate mRNA technology. It demonstrated that Pfizer’s post-Upjohn identity as a manufacturing and regulatory powerhouse was not a narrative convenience. It was operational reality.
Pfizer’s India patent portfolio tells a story that is easy to misread. At first glance, 1,037 filings and 152 grants suggests a company flooding the Indian Patent Office with applications. The context matters. India’s patent regime, reformed in 2005 to comply with TRIPS, applies a stricter standard of patentability than the United States or Europe. Section 3(d) of the Indian Patents Act specifically excludes new forms of known substances unless they demonstrate significantly enhanced efficacy. For a company like Pfizer, whose global portfolio includes incremental formulation improvements alongside genuinely novel molecules, the Indian system functions as a filter.
The 152 grants represent molecules and formulations that cleared that filter. Among OPPI member companies filing patents in India, Pfizer ranks eighth by total filings, placing it behind some companies with larger India-specific research operations but ahead of most multinational peers. The filing pattern spans from 1994,before India’s product patent regime existed,through 2026, reflecting three decades of sustained intellectual property investment in a market where patent enforcement remains challenging and generic competition is intense.
What the numbers do not capture is the strategic shift in what Pfizer files. The early filings skewed toward small-molecule formulations and manufacturing processes. The recent filings increasingly involve biologics, mRNA-related technologies, and oncology compounds,mirroring the company’s global pivot toward innovation-driven therapeutics. The patent portfolio, in other words, is a paper trail of corporate transformation.
Pfizer Ltd, listed on the Bombay Stock Exchange under the ticker PFIZER, is one of the longest-operating multinational pharmaceutical subsidiaries in India. The entity predates India’s independence, making it part of a small cohort of foreign pharma companies,alongside GSK, Abbott, and Sanofi,that maintained continuous operations through the license raj, the 1970 Patents Act that abolished product patents, and the subsequent reintroduction of product patents in 2005.
The survival required adaptation that most multinational playbooks do not accommodate. When India eliminated pharmaceutical product patents in 1970, effectively legalizing generic competition against patented drugs, Pfizer could not rely on the exclusivity-driven pricing model that sustained its business elsewhere. It stayed anyway. The Indian subsidiary built relationships with hospitals and physicians that extended beyond individual molecules, marketed a portfolio that mixed patented imports with locally manufactured generics, and maintained a presence through decades when the financial logic of operating in India was, at best, marginal.
That persistence now looks prescient. India’s pharmaceutical market is among the fastest-growing in the world, and Pfizer’s BSE-listed entity gives it a regulated, transparent vehicle for participating in that growth. The subsidiary operates under Indian corporate governance requirements, files with SEBI, and maintains the institutional infrastructure,regulatory relationships, distribution networks, medical affairs teams,that a new entrant would take years to build. When Pfizer’s global leadership evaluates India as a market for its newest molecules, the entity is already there.
Sources: Pfizer Inc Annual Reports 2014–2024 (10-K/Proxy filings). Pfizer Ltd (India) Annual Reports FY2016–FY2025. Indian Patent Office (patent filing data). BSE India (listed entity data). OPPI member directory.